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THE report of the red dye, prontosil, as a chemotherapeutic agent (Domagk,
1935) was followed by the demonstration that its activity depended upon
sulphanilamide. Analogues with a wider antibacterial range soon became avail-
able. A decade getting to know the sulphonamides was followed by another
learning to use penicillin. The nineteen-fifties witnessed the introduction of broad-
spectrum antibiotics and several further antistaphylococcal agents (Table 1).
TABLE 1.
HISTORICAL BACKGROUND TO THE CHEMOTHERAPEUTIC AGENTS.
YEAR DRUG SOURCE YEAR DRUG SOURCE
1935 - Sulphonamides - Germany 1952 - Isoniazid - U.S.A.
1939 - Tyrothricin - U.S.A. 1953 - Tetracycline - U.S.A.
1940 - Penicillin - Gt.Britain 1955 - Novobiocin - U.S.A.
1944 - Streptomycin - U.S.A. 1955 - Oleandomycin - U.S.A.
1945 - Bacitracin - U.S.A. 1956- Vancomycin - U.S.A.
1946 - Para-amino.salicylic 1956 - Amphotericin - U.S.A.
acid (P.A.S.) - Sweden 1957 - Ristocetin - U.S.A.
1947 - Polymyxin - Gt. Britain
an U.S.A. 1957 - Kanamycin - Japan an1U.S.A. 1958 - Griseofulvin -Gt.Britain
1948 - Chlortetracycline - U.S.A. 1959 - Paromomycin - U.S.A.
1949 - Neomycin - U.S.A. 1959 - Phenethicillin - Gt.Britain
1950 - Oxytetracycline - U.S.A. 1960 - Methicillin - Gt.Britain
1951 - Nystatin - U.S.A. 1961 - Ampicillin - Gt.Britain
1952 - Erythromycin - U.S.A. 1961 - Brocillin - Gt.Britain
It seems likely that the present decade will be dominated by a new family of
semi-synthetic penicillins. Thus far we have seen and used only a few, but one
of them has already dealt a major blow at naturally resistant staphylococci, by
its indifference to the penicillinase which they produce. The potential for
providing new synthetic penicillins appears to be limitless. It is hoped that they
will be chemically dissimilar, for only on this basis can-they be expected to be
therapeutically distinctive.
*Based on the Beecham Lecture delivered to the Ulster Medical Society on November 9, 1%91.
25What has been the impact of a quarter-century of sulphonamides penicillin and
broad-spectrum antibiotics on the natural history ofinfections? ThatiswhatFinland
and his colleagues at the Boston City Hospital set out to assess in a sweeping,
twenty-two year survey. They have reviewed the changing pattern of septicamia,
meningitis, empyema, and autopsy material in the hospital during certain years
carefully chosen to reflect the changing fashion in chemotherapy. The year 1935
was selected as a baseline for the pre-sulphonamide era; 1941 to reveal the impact
of the sulphonamides before they had been joined by penicillin; 1947 when both
penicillin and streptomycin had been widely used; and 1957 to define recent
trends influenced by most or all currently available antibiotics (Table 2).
TABLE 2.
THE NUMIBER OF PATIENTS ADIMITTED TO THE BOSTON CITY HOSPITAL
WITH SEPTICAEMIA, MFNINGITIS, AND ENIPYEMIA DURING 1935 COMPARED
wiVrH 1957.
1935 19'57
No. % MORTALITY No. % MORTALITY
Septiconaia - - 286 ... 60 ... 588 ... 40
Gram positive - 250 ... 67 ... 406 ... 33
Gram negative - 36 ... 42 ... 182 ... 54
Meningitis - - 55 ... 80 ... 90 ... 20
Empyema - - 172 ... 22 ... 83 ... 32
During 1935 about three hundred septicamic patients were hospitalized and
three-fifths died; by 1957 nearly two-fifths died. Thus, as a result of all advances
between 1935 and 1957, an additional one in five septicamic patients can be saved.
Interestingly enough, that decline in mortality coincides with the use of the
sulphonamides during the years 1935-41. Since then, even with the advantage
of penicillin, streptomvcin and the broad-spectrum antibiotics, the mortality rate
has indeed inicreased. By way of contrast, meningitis and empyema have become
less of a challenge although they have by no means been overcome.
Over the years the bacteria isolated from these infections have changed
significantly and the changing flora does, in fact, mirror both the success and
failure of the antibiotics. In essence, the antibiotic era has witnessed a change
from pneumococcal and streptococcal to staphylococcal and coliform septicamia.
The significance of the findings from the unique survey at the Boston City
Hospital might be less certain had they come from other centres, but the special
circumstances of this study comnmand respect and authority. In the first place
it was conducted at a large general metropolitan hospital admitting four patients
every hour round the clock, and performing three autopsies daily throughout
the years of the survey. To such a wealth of clinical material may be added the
uniformitv of viewpoint which makes this comparative study worthwhile.
26Throughout the years the senior author of the report, Dr. Maxwell Finland, has
himself been responsible for the management of infections in the hospital. That
has ensured both the hospital's continuous interest in the study of infectious
disease and also the high yield of bacteriological data without which such an
investigation would have been valueless. It is hoped that he and his co-workers
will pursue this survey to include the impact of the new synthetic penicillins,
agents which now show promise of controlling the remaining problems of
staphylococcal and Gram-negative infections.
THE SULPHONAMIDE FAMlILY.
The absorbable sulphonamides and the poorly-absorbed or "gut-active"
compounds have now been joined by long-acting sulphonamides, which are more
extensively bound to plasma protein. The more prolonged blood levels claimed
TABLE 3.
RELATIVE COST OF VARIOUS AGENTS USED IN THE TREATMENT OF
ACUTE URINARY TRACT INFECTIONS.
ONE ONEWEEK'S
CHEMOTHERAPEUTIC TABLET COSTS COSTS
AGENT (G) (pence) (shillings)
Sulphadimidine ... 0.5 ... 1 ... 7
Sulphamethoxypyridazine ... 0.5 ... 7 ... 5
Bimex, comprising: ... 0.5
Sulphadimidine ... 0.375 3.5 4
Sulphamethoxypyridazine .. 0.125 3
Nitrofurantoin ... 0.05 ... 8 ... 19
Tetracycline ... 0.25 ... 18 ... 43
Chloramphenicol ... 0.25 ... 12 ... 30
for these new agents does not necessarily imply superiority for protein-bound
sulphonamide is not anti-bacterial (Newbould and Kilpatrick, 1960). What is
needed of a drug is high diffusibility and high tissue concentration, and this is
more readily achieved when the drug is not bound to plasma protein. Thus,
long-acting sulphonamides are particularly contraindicated in the management of
meningitis, or infected pleural effusion. It is difficult to conceive any situation
in which they are clearly preferable to the present range of established absorbable
sulphonamides. One of the chief current indications for any of the absorbable
sulphonamides is acute infection of the urinary tract.
The attraction of these compounds is universally enhanced by their
comparatively low cost (Table 3).
THE PENICILLIN FAMILY.
The penicillin story comprises several distinct chapters. Following Fleming's
classical observations on the antibacterial properties of the mould, Penicillium
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CQ-(Fleming, 1929), there was a hiatus of eleven years until Florey, Chain, and their
colleagues introduced penicillin into the realm of clinica medicine. (Chain et al.,
1940). This was soon to be followed by its mass production, and by the develop-
ment of new salts and other compounds designed to improve its already high
therapeutic activity. Large-scale production of pure benzylpenicillin by sub--
merged oerobic culture of the mould, penicillium chrysogenum, is now being
challenged by a series of semi-synthetic penicillins. To the penicillin nucleus,
6-amino-penicillanic acid, which is produced by fermentation, may be attached
various side chains (Batchelor et al., 1959); this synthetic manipulation holds the
potential promise of an endless serie of new penicillins. If it is remembered that
phenoxymethylpenicillin is penicillin V, then in turn have come phenoxyethyl-
TABLE 4.
THE DAILY DOSE AND-COST OF TIJE NEW PENICILLINS.
TABLET DAILY
NAME OF PENICILLIN SIZES DOSE COST
(mg.) (ggm.)
Methyl - - PenicillinV .V 125 .
zlzz
~~~~~~~2501 2/
Phenoxy-Ethyl-Penicillin - Phenethicillin ... 125
\ // (Broxil) 250 ... ... 4/4
Propyl - - Brocillin ... 125 1 4/4
Ultrapen ... 250 1 . 4
Dimethoxyphenylpenicillin - Methicillin. ... Intramusc.
Celbenin ... Injection ... 6 ... 60/-
Staphcillin ... 1 gm. 4-hourly
Aminophenylacetamido-
penicillanic Acid - - Ampicillin ... 250 ... 1 ... 12/3
Penbritin ...
penicillin (phenethicillin, 'Broxil') and phenoxypropylpenicillin ('Brocillin';
'Ultrapen') (Table 4). They are not destroyed by gastric acid, and are all well
absorbed following oral administration. Higher blood levels are attained with
the most recent ones, but their relative merits still need to be assessed. It seems
that none of them is as effective as benzylpenicillin for any but staphylococcal
infections, which will be discussed later. Thus, the introduction of novel synthetic
penicillins has not changed the treatment of pneumococcal pneumonia,
gonorrhaea, meningococcal, and streptococcal infections, syphilis, actinomycosis,
or anthrax.
Methicillin (dimethoxyphenylpenicillin, 'Celbenin,' 'Staphcillin') (Douthwaite
et al., 1960, 1961; Stewart et al., 1960) is a synthetic penicillin which is unaffected
29by staphylococcal penicillinase. It is therefore the antibiotic of choice for drug
resistant staphylococcal inifections. This, its sole indication, should be respected.
Undoubtedly it will be, for it must be given by injection (it is destroyed by
gastric acid) every four to six hours (it is rapidly absorbed and excreted) and it
is expensive (a week's course of treatment costs £21).
Another recent synthetic penicillin is ampicillin ('Penbritin') (Rolinson and
Stevens, 1961) which is active when given by mouth and has a broad-spectrum
activity against both gram-positive and gram-negative organisms. Its range is
about the same as the bacteriostatic tetracyclines, but it carries the advantages
of being bactericidal. For the present, it should be considered as an alternative
to tetracycline, or instead of penicillin-streptomycin or penicillin-sulphonamide
mixtures, and for proteus infections (Brumfitt et al., 1962). Ampicillin itself may
be but the forerunner of other more effective broad-spectrum bactericidal agents;
if so, a major advance in chemotherapy will have been achieved.
TIiE TETRACYCLINE FANILY.
Chlortetracyclinie ('Aureomycin'), oxytetracycline ('Terramycin'), tetracycline
('Achromycin,' Tetracyn') and demethylchlortetracycline ('Ledermycin') are so
similar in their antimicrobial range, indications, and complications that there is
little to choose between them. There is no point in switching from one to
another because of bacterial resistance, for they would all prove ineffective.
Thus, the clinician is wise to keep to the one to which he is accustomed. A slight
advantage claimed for demethylchlortetracycline is that higher and more
prolonged blood levels allow it to be given every twelve hours rather than every
six hours.
The tetracyclines are bacteriostatic for most gram-positive and gram-negative
bacteria, the spirochates, all rickettsik, and for the small group of psittacosis-
lymphogranuloma viruses. Indications for their use (James, 1957) may be broadly
grouped as follows:
1. An alternative to penicillin, particularly if the patient is hypersensitive to
penicillin. Let us face the fact that they are a poor alternative to penicillin
in the management of gram-positive infections, and these bacteriostatic
agents are markedly inferior to bactericidal drugs in the control of such
severe infections as subacute bacterial endocarditis.
2. Sulphonamide-resistant urinary tract infections.
3. Brucellosis.
4. All rickettsial infections.
5. Virus infections-psittacosis, lvmphogranuloma venereum, trachoma, in-
clusion conjunctivitis.
6. Pneumonia associated with raised cold hamagglutinins.
7. Acute or relapsing amcebic dysenterv, used in conjunction with the emetine
group of drugs.
308. Acute exacerbations of chronic bronchitis. This is probably the most
frequent use of the tetracycline antibiotics, for they can be expected to
control a mixed infection of pneumococci, streptococci, staphylococci, and
haemophilus influenz2e. It remains to be seen whether tetracycline will be
superseded by ampicillin, which is alleged to have the same broad spectrum,
and is bactericidal rather than bacteriostatic (Fig. 1).
ANTISTAPHYLOCOCCAI AGENTS.
Antibiotic-resistant staphylococcal infections have become commonplace in
hospitals during the last decade. Indeed most antibiotics introduced during that
time have been directed towards control of this hospital menace. For penicillin-
sensitive staphylococcal infections, the antibiotic of choice is still the well-tried
crystalline benzylpenicillin. It may be combined with procaine penicillin,
benethamine or benzathine penicillin to produce more persistent blood levels.
Simultaneous use of the renal tubular blocking agent-probenecid ('Benemid')
will approximately double the blood level of penicillin, an advantage which may
be worth considering especially in protracted infections, or where it is required
to lessen the number of injections in children.
The introduction of methicillin has eased, at least for the present, the manage-
ment of penicillin-resistant staphylococcal infections. It is given by injection in
a dose of one gram every four to six hours.
The manufacturers now acclaim the value of phenoxypropylpenicillin
('Brocillin'; 'Ultrapen') for what they term the mildly-resistant staphylococcal
infection. Not only does this antibiotic need further evaluation but the clinical
condition for which it is being suggested needs to be defined more clearly.
If it succeeds, then the least important aspect of an antibiotic is its cost, but
the economic implications are of interest particularly since some antibiotics are
imported (Table 5).
TABLE 5.
THE C(OST OF TREATING A STAPHYLOCOCCAL INFECTION IN GREAT BRITAIN
IN OCTOBER, 1961, WITH VARIOUS ANTIBIOTICS.
ONE TABLET ONE WEEK'S
ANTI-STAPHYLOCOOCAL OR VIAL COSTS COSTS
AGENTS (grammes) (sh.)
Benzyl penicillin ... 0.5 megaunit ... .Id. 20
Methicillin ... 1 ... 13/- ... 416
Tetracvcline ... 0.25 ... 1/6 ... 43
Chloramphenicol ... 0.25 ... 1/- ... 30
Erythromycin ... 0.25 ... lOd. ... 24
Novobiocin ... 0.25 ... 2/- ... 58
Oleandomycin ... 0.25 ... 2/6 ... 72.5
Ristocetin ... 0.5 ... 32/- ... 660
Kanamycin ... 1 ... 30/- ... 210
Vancomycin ... 0.5 ... 50/- ... 1,400
31
KSPECIAL INDICATIONS.
Certain chemotherapeutic agents have a limited range of activity but within
these limitations they may be dramaticallv successful. It is advisable to endeavour
to restrict their use to such responsive disease states (Table 6).
Griseoftlvin was originally isolated from a penicillium species as long ago as
1939, but has onlv been recognised since 1958 as a valuable oral antibiotic against
animal and human ringw7orm. It is indicated for superficial dermatophyte
infection and it is ineffective in the management of systemic mycoses or
moniliasis.
TABLE 6.
SPECIAL CONDITIONS IN W\rHICH CERTAIN ANTIMICROBIAL AGENTS
SHOULD BE CONSIDFRED.
INFFCTION
Dermatophytosis
Systemic mycoses
Moniliasis
Due to pseudomonlas pyocyanea
Diphtheria
Amcebiasis
Typhoid fever
Hepatic coma (gut sterilisation)
Meningitis due to haneophilus influenzx
Meningococcal meningitis
Tuberculosis
CHEMOTHFRAPFUTIC AGENT
... Griseofulvin
Amphotericin B
Nystatin
... Polymyxin
Colomycin
Erythromycin
(together with antitoxin)
... Paromomycin
(togetherwith other antiamoebic agents)
... Chloramphenicol or ampicillin
... Neomvcin
... Chloramphenlicol
... Sulphoilamtlides
Streptomvcin, isoniazid and P.A.S.
Amphiotericin B is a polyene antifungal anltibiotic obtained from streptomyces
nodosus. It should be considered in the management of such serious deep-
seated mycoses as blastomycosis, coccidioidomvcosis, cryptococcosis (torulosis),
histoplasmosis, and disseminated moniliasis. Amphotericin B is poorly absorbed
following oral administration so it is usually administered in dextrose solution by
slow intravenous infusion.
Nystatin, a polyene antibiotic obtained from streptomyces noursei, is active
against several fungi and yeasts but is particularly indicated for Monilia (Candida)
albicans infections. Whenever possible, it should be given topically in the form
of suspension, ointment, pessary or by inhalation, for infections of the mouth,
skin, vagina or respiratory tract. It is poorlv absorbed from the gut, so, following
oral administration, its effect is primarily in the intestinal lumen. It should be
32given by mlouth with tetracycline if proloniged treatment with such a broad-
spectrm antbiotic is indicated. spectrum anti Iltl 1SC1CtC.
Polymyxin was isolated from bacillus polymyxa, simultaneously but indepen-
dently in Great Britain (Ainsworth et al., 1947) and in the United States
(Benedict and Langlykke, 1947; Stansly et al., 1947). It is available as polymyxin
B sulphate powder in vials containing 500,000 units. It is not absorbed from the
gut, but it can be administered by intravenous, intramuscular, intrathecal, sub-
conjunctival, and intrapleural routes. Polymyxini is reserved for pseudomonas
infections.
Colomycin is a polypeptide antibiotic similar to polymyxin in its range of
activity and with reciprocal cross-resistance but apparently less toxic. The side-
effects of neurotoxicity and nephrotoxicity are infrequent and only transient
TABLE 7.
IHE Cosr oi SoiNI ANII-TUBERCULOUS DRUGS, OCTOBER, 1961.
ONE DAY'S ONE WEEK'S
ANTI-TUBERCULOUS DOSE Cosr1s
DRUGS (G.) CosIs (shillings)
Streptomycin ... 1 ... 1/6 ... 10.5
P.A.S. ... 12 ... 9d. ... 5
Isoniazid ... 0.3 ... IId. ... 0.75
Pycamisan B.D. ... 8 cachets ...
P.A.s. ... 12 1/ .. 1.
lsoniazid 1 .. 0.3.
10.5
(Kirby and Roberts, 1961). It is likely that colonimcin will supplant polymyxin
in the management of pseudomonas infections, and it should also be considered
for other infections due to gram-negative bacilli.
Erythbro'mycin is superior to peniicillin in the sterilisation of diphtheria carriers.
Forbes (1954) obtained negative cultures in fourteen carriers who had failed to
respond to two courses of penicillin. It should be given with antitoxin to patients
with diphtheria. It has been relegated by methicillin to a reserve position as an
antistaphylococcal agent, but its potential value for this purpose remains. It would
be indicated once again if staphvlococcal infections developed resistance to the
current svnthetic penicillins.
ChIloramphenicol remains the drug of choice for the treatment of Salmonlella
infections; and also for haemophilus influenzx meningitis because it crosses the
blood-brain barrier so effectively. It remains to be seen whether the bactericidal
effect of ampicillin in gram-negative infectionis eventually proves superior,
particularly in preventing relapses of typhoid fever.
Neovnycin and pa'rownonzycin are effective in suppressing gut infections, and
should be considered especially (a) as part of the management of impending
33hepatic coma; (b) as an additional measure in intestinal amoebiasis; (c) to control
a virulent epidemic of gastroenteritis in a closed community; and (d) also, when
necessary, pre-operatively.
Streptomycin, isoniazid and paaraminosalicydic acid remain the standard drugs
used in the chemotherapy of tuberculosis (Table 7). Their use is well established
and does not merit special attention.
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